|
End-of-day quote
Swiss Exchange
|
||
| - CHF | - |
|
| 02:55pm | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 09-15 | Legend Biotech taps Novartis veteran Zhang as CEO | RE |
| Market Cap | 157B 136B 129B 117B 219B 15,064B 220B 1,535B 593B 7,640B 590B 577B 24,354B | P/E 2026 * |
17.4x | P/E 2027 * | 13.5x |
|---|---|---|---|---|---|
| Enterprise Value | 205B 177B 168B 152B 285B 19,619B 287B 2,000B 773B 9,951B 768B 751B 31,718B | EV / Sales 2026 * |
3.29x | EV / Sales 2027 * | 3.31x |
| Free-Float |
59.05% | Yield 2026 * |
6.25% | Yield 2027 * | 6.3% |
Last Transcript: Pfizer Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 64 | 31/12/2018 |
Cecile Guegan
DFI | Director of Finance/CFO | 55 | 15/08/2026 |
Rady Johnson
CMP | Compliance Officer | 65 | 30/11/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 68 | 31/08/2007 |
Shantanu Narayen
BRD | Director/Board Member | 62 | 26/09/2013 |
Albert Bourla
CHM | Chairman | 64 | 31/12/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.15% | +1.21% | +48.79% | +99.17% | 1,013B | |
| +0.03% | +0.07% | +51.47% | +64.51% | 644B | |
| -0.20% | +4.62% | +21.39% | +70.53% | 465B | |
| +0.53% | +3.42% | +39.21% | +38.70% | 352B | |
| +0.39% | +2.22% | +17.02% | +23.87% | 264B | |
| +0.17% | +2.19% | +6.33% | +10.93% | 253B | |
| +0.19% | -3.81% | +37.81% | +43.02% | 203B | |
| -1.20% | -6.64% | -23.23% | -59.10% | 188B | |
| +0.94% | +1.39% | +33.21% | +95.29% | 181B | |
| Average | +0.23% | -1.08% | +25.78% | +42.99% | 395.97B | |
| Weighted average by Cap. | +0.33% | +0.01% | +34.15% | +59.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 62.24B 53.93B 50.98B 46.28B 86.74B 5,970B 87.25B 609B 235B 3,028B 234B 229B 9,652B | 59.77B 51.79B 48.95B 44.44B 83.29B 5,734B 83.79B 584B 226B 2,908B 225B 220B 9,269B |
| Net income | 8.9B 7.71B 7.29B 6.62B 12.4B 854B 12.48B 87.03B 33.63B 433B 33.43B 32.69B 1,380B | 11.08B 9.6B 9.08B 8.24B 15.44B 1,063B 15.53B 108B 41.87B 539B 41.62B 40.7B 1,718B |
| Net Debt | 47.48B 41.15B 38.89B 35.31B 66.18B 4,555B 66.57B 464B 179B 2,310B 178B 174B 7,364B | 40.98B 35.51B 33.57B 30.47B 57.11B 3,931B 57.45B 401B 155B 1,994B 154B 151B 6,356B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
